4 assets in MELAS Syndrome

Therapeutic assets addressing MELAS Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Sonlicromanol MELAS Syndrome	Khondrion BV	P3	BB (70)
Zagociguat MELAS Syndrome	Tisento Therapeutics	P2	CCC (55)
Tti-0102 MELAS Syndrome	Thiogenesis Therapeutics, Inc.	P2	CCC (53)
Glycerol Tributyrate MELAS Syndrome	George Washington University	P1/2	CCC (48)